149 related articles for article (PubMed ID: 31184601)
1. [Virus-Like Particles as an Instrument of Vaccine Production].
Syomin BV; Ilyin YV
Mol Biol (Mosk); 2019; 53(3):367-379. PubMed ID: 31184601
[TBL] [Abstract][Full Text] [Related]
2. Virus-Like Particles as an Instrument of Vaccine Production.
Syomin BV; Ilyin YV
Mol Biol; 2019; 53(3):323-334. PubMed ID: 32214478
[TBL] [Abstract][Full Text] [Related]
3. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
4. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
Garg H; Sedano M; Plata G; Punke EB; Joshi A
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
[TBL] [Abstract][Full Text] [Related]
5. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
6. Major findings and recent advances in virus-like particle (VLP)-based vaccines.
Mohsen MO; Zha L; Cabral-Miranda G; Bachmann MF
Semin Immunol; 2017 Dec; 34():123-132. PubMed ID: 28887001
[TBL] [Abstract][Full Text] [Related]
7. The Respiratory Syncytial Virus Phosphoprotein, Matrix Protein, and Fusion Protein Carboxy-Terminal Domain Drive Efficient Filamentous Virus-Like Particle Formation.
Meshram CD; Baviskar PS; Ognibene CM; Oomens AGP
J Virol; 2016 Dec; 90(23):10612-10628. PubMed ID: 27654298
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.
Schweneker M; Laimbacher AS; Zimmer G; Wagner S; Schraner EM; Wolferstätter M; Klingenberg M; Dirmeier U; Steigerwald R; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331098
[TBL] [Abstract][Full Text] [Related]
9. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.
Kushnir N; Streatfield SJ; Yusibov V
Vaccine; 2012 Dec; 31(1):58-83. PubMed ID: 23142589
[TBL] [Abstract][Full Text] [Related]
10. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
11. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
12. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
[TBL] [Abstract][Full Text] [Related]
13. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
14. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
15. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
[TBL] [Abstract][Full Text] [Related]
16. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
[TBL] [Abstract][Full Text] [Related]
17. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
18. Virus-like particles in picornavirus vaccine development.
Dong H; Guo HC; Sun SQ
Appl Microbiol Biotechnol; 2014 May; 98(10):4321-9. PubMed ID: 24647496
[TBL] [Abstract][Full Text] [Related]
19. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
20. Enveloped virus-like particle platforms: vaccines of the future?
Pitoiset F; Vazquez T; Bellier B
Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
